Document is current

Article History

Received: 2 February 2024

Accepted: 23 May 2024

First Online: 2 August 2024

Acknowledgements

: Thanks to R. Møller and D. Hass at the Department of Infectious Diseases, Rigshospitalet for their help with the data collection. Thanks to T. McDonald and staff at the Exeter Clinical Laboratory International, Blood Sciences, Royal Devon and Exeter Hospital, University of Exeter Medical School for performing the biochemical analyses.

: The datasets generated during and/or analysed during the current study are not publicly available due to reasons of sensitivity and data protection regulations but are available from the corresponding author upon reasonable request. Data are located in controlled access data storage in REDCap at Region Hovedstaden, Denmark.

: Open access funding provided by National Hospital. The study was supported by a grant from the CF-Trust (SRC-CFRD 019). MRR and DS are supported by US Public Health Service research grant R01 DK97830 (to MRR).

: TPA holds stocks in Novo Nordisk. All other authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work.

: BUN, JAMS, MRR, DF-J and DS designed the study. BUN was responsible for data acquisition and BUN and DS performed data analysis. BUN, IHMM, RK-M, TLK, TP, JAMS, MRR, TPA, DF-J and DS interpreted the data, contributed to drafting the manuscript and approved the final version. BUN is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.